Hamlet BioPharma AB (publ) (BST:7ZT)

Germany · Delayed Price · Currency is EUR

0.4760

0.00 (0.00%)

At close: Oct 29, 2026

Market Cap	99.86M +10.4%
Revenue (ttm)	4.94K -73.7%
Net Income	-5.02M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.4760
Day's Range	n/a
52-Week Range	0.3700 - 0.8020
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Hamlet BioPharma AB

Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. Hamle...

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 6

Stock Exchange Stuttgart Stock Exchange

Ticker Symbol 7ZT